GNNSF (Genscript Biotech) Moat Score: 6/10 (As of Jul. 05, 2026)


GNNSF Genscript Biotech Corp GNNSF
66 GF Score
Price $1.60
GF Value $2.48
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genscript Biotech Moat Score?

Genscript Biotech GNNSF 66 Moat Score is 6 as of Jul. 05, 2026. GuruFocus rates GNNSF with a GF Score™ of 66/100 and a GF Value™ of $2.48 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 1,395 Biotechnology companies, Genscript Biotech ranks better than 98.92% on this metric.

Genscript Biotech has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Genscript Biotech has Narrow Moat: Genscript Biotech has a strong narrow moat due to its leading position in gene synthesis and cell therapy, supported by valuable patents and consistent innovation. However, the biotech sector's competitive nature and moderate customer switching costs prevent it from achieving a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Genscript Biotech might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Genscript Biotech  (OTCPK:GNNSF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Genscript Biotech Moat Score Related Terms

GNNSF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Genscript Biotech's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genscript Biotech Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's Moat Score distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's Moat Score falls into.


GNNSF
66GF Score
Genscript Biotech Corp GNNSF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Genscript Biotech (GNNSF) has a Moat Score of 6 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Genscript Biotech ranks #15 out of 1395 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Genscript Biotech's Moat Score too high?
Genscript Biotech's current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. Genscript Biotech's value of 6 is 200% above this industry median. Based on the distribution chart, Genscript Biotech ranks #15 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #15 out of 1395 companies for Moat Score. This places Genscript Biotech in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Genscript Biotech's value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genscript Biotech's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.48, compared to a current price of $1.60 — trading 35.5% below its estimated fair value. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. Genscript Biotech's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Moat Score is 6 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genscript Biotech (GNNSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued. The current stock price of $1.60 is trading 35.5% below its estimated GF Value™ of $2.48. GuruFocus considers Genscript Biotech to be Significantly Undervalued.

Key valuation signals for GNNSF:

  • Moat Score: 6
  • GF Value™: $2.48 vs. price of $1.60 (35.5% below fair value)
  • GF Score™: 66/100 with 4 warning signs
  • Industry Position: 200% above the Biotechnology median (#15 of 1395)

No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genscript Biotech Business Description

Other Exchanges 01548:Hong KongG51:Germany
Address 860 Centennial Avenue, Piscataway, NJ, USA, 08854
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score

Get the complete analysis for GNNSF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.60
Price
$2.48
GF Value